Merit Medical (MMSI) has disclosed a new risk, in the Corporate Activity and Growth category.
Merit Medical faces a potential business risk following the adoption of trading arrangements by its top executives, Neil Peterson and Raul Parra. Peterson’s Rule 10b5-1 Trading Plan and Parra’s Rule 10b5-1 Trading Plan involve the sale of significant quantities of company stock, subject to certain conditions. The execution of these plans may signal changes in insider confidence and could influence the market’s perception of the company’s stability. These arrangements, detailed in Exhibits 10.1 and 10.2 of their Quarterly Report, underscore a need for scrutiny by investors and analysts regarding potential impacts on Merit’s stock performance.
The average MMSI stock price target is $92.00, implying 20.06% upside potential.
To learn more about Merit Medical’s risk factors, click here.
